FAQs on Generics

 

Evolution of Generics - Overview

Generic medicines had major milestones including, Regulatory laws to support generic development, which encouraged manufacturers to explore the generics market. These legislations also provided the physicians a confidence to prescribe a substitute for a brand-name drug and it eventually benefitted patients, as generic manufacturers met critical needs of patients across the globe.

FAQs on Generics

FAQs on Generics

Q1: What are generic drugs?

Ans: Generic drugs are pharmaceutical drugs, which are identical copies of the originator drug product and have the same API, dosage, intended use, side effects, route of administration, risks, safety and strength as the innovator drug, but it may differ in some characteristics such as, the manufacturing process, formulation, excipients, colour, taste and packaging. In other words, a generic drug is therapeutically equivalent to a branded drug and therefore, can be substituted with its brand-name counterpart.

Q2: Why do generic drugs cost less than an innovator drug?

Ans: Generic drugs are more cost-effective when compared to the innovator drug, because generic drugs do not have to repeat the costly and lengthy pre-clinical and clinical studies, that are required for the innovator medicines to demonstrate safety and effectiveness and instead, the generic medicines need to prove only the pharmaceutical equivalency for their product.

Q3: Are generic drugs as good as innovator drug?

Ans: Yes, generic drugs have the same quality, efficacy and are safe as brand-name medicines. The lower price of these drugs doesn’t indicate that they are of inferior quality, because generic medicines just like brand-name drugs, have to go through a rigorous drug approval process to market their drug product and the pharmaceutical companies are required to submit the generic drug application, showing that, their drug product has the same clinical benefit as the brand-name medicines and are suitable to be used as a substitute for their respective brand-name drug.

Q4: Why do generic drugs look different than the brand-name drug product?

Ans: Generic drug products must be bioequivalent to branded drugs and have the same API as Innovator drugs. However, there can be minute differences in the generic drug products w.r.t shape, labeling (minor differences), packaging and inactive ingredients like, color, flavors and preservatives; but the effectiveness of the drug must remain the same.

Q5: What’s involved in reviewing and approving generic drug applications in the US?

Ans: Any pharmaceutical company that has to market its generic drug product in the US should comply with all the US FDA’s Regulatory requirements for generic drug filing and must show that:

  • The generic drug is “Pharmaceutically/Therapeutically equivalent” to the brand
  • The manufacturer is capable of making the drug correctly and consistently
  • The “active ingredient” is the same as that of the brand
  • The right amount of the active ingredient gets to the place in the body, where it has an effect
  • The "inactive" ingredients of the drug are safe
  • The drug does not break down over time
  • The container in which the drug will be shipped and sold is appropriate
  • The label is the same as the brand-name drug’s label
  • Relevant patents or legal exclusivities are expired

Q6: Does every brand-name drug have a generic drug?

Ans: No. Every brand-name drug doesn’t have a generic version. New drugs are manufactured under patent protection for up to twenty (20) years. This means that no other drug can be manufactured and marketed during this period, until the expiration of the patent. However, some drugs may never have generic versions for their product, due to difficulty in manufacturing or in case the generic drug product may deem to be unprofitable.

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​